Bliss Gvs Pharma Balance Sheet Annual

Trade

BSE: 506197 | NSE: BLISSGVS | ISIN: INE416D01022 | Sector: Biotechnology & Drugs

132.25 +0.75 (0.57%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Cash Equivalents	215.62	2.47	8.36	2.40
Short Term Investments	11.49	47.61	123.96	65.15
Cashand Short Term Investments	227.11	72.57	145.87	77.78
Accounts Receivable- Trade Net	404.35	385.17	392.75	463.82
Total Receivables Net	407.33	428.13	406.94	470.00
Total Inventory	118.45	154.66	177.45	119.05
Other Current Assets Total	58.73	39.59	42.58	96.94
Total Current Assets	811.62	697.37	776.03	765.20
Property/ Plant/ Equipment Total- Net	369.38	372.91	294.82	227.82
Goodwill Net	7.71	7.71	7.71	7.71
Intangibles Net	0.11	0.23	0.38	0.58
Long Term Investments	12.39	57.55	4.36	62.70
Other Long Term Assets Total	12.66	5.26	4.53	1.16
Total Assets	1,213.87	1,156.85	1,108.75	1,076.79
Accounts Payable	60.97	86.39	92.61	74.22
Current Portof LT Debt/ Capital Leases	54.97	12.48	0.94	22.43
Other Currentliabilities Total	43.89	42.14	55.19	38.52
Total Current Liabilities	159.82	193.26	233.09	203.64
Long Term Debt	35.59	40.69	23.22	32.60
Capital Lease Obligations	9.28	2.72	3.49	1.83
Total Long Term Debt	44.87	43.41	26.71	34.43
Total Debt	99.84	101.90	109.39	121.90
Deferred Income Tax	3.59	0.00	1.32	8.21
Minority Interest	35.79	33.53	27.76	19.66
Other Liabilities Total	2.60	2.76	1.16	2.60
Total Liabilities	246.68	272.96	290.04	268.53
Common Stock Total	10.47	10.42	10.37	10.31
Other Equity Total	956.72	-22.75	-17.01	-9.30
Total Equity	967.19	883.90	818.70	808.25
Total Liabilities Shareholders' Equity	1,213.87	1,156.85	1,108.75	1,076.79
Total Common Shares Outstanding	10.47	10.42	10.37	10.31
Tangible Book Valueper Share Common Eq	91.64	84.10	78.19	77.56
Cash	-	22.49	13.56	10.24
Prepaid Expenses	-	2.42	3.19	1.43
Property/ Plant/ Equipment Total- Gross	-	449.29	333.97	275.67
Accumulated Depreciation Total	-	-79.18	-61.30	-50.23
Note Receivable- Long Term	-	15.83	20.90	11.61
Accrued Expenses	-	6.24	2.61	3.43
Notes Payable/ Short Term Debt	-	46.01	81.74	65.04
Additional Paid- In Capital	-	26.99	21.28	14.76
Retained Earnings( Accumulated Deficit)	-	869.23	804.07	792.48